What’s the forecast for biotech in 2012? Do investors think it is a good time to invest in biotechnology? Are they interested in taking on early stage companies?
At the BIO CEO & Investor Conference opening plenary, the BIO Industry Analysis team released results from their Investor Perception Study and, afterwards, a panel of portfolio managers and senior buy-side analysts fielded a range of question about the challenges and opportunities facing the industry. David Gluckman, M.D., managing director and co-head of North American Life Sciences, moderated the panel that included:
Alexander J. Denner, PhD, (former) Managing Director, Icahn Associates
Rajiv Kaul, Portfolio Manager, Fidelity Select Biotechnology Portfolio, Fidelity
Greg Martinez, Portfolio Manager, Diamondback Capital Management LLC
Deepa R. Pakianathan, PhD, General Partner, Delphi Ventures
Tags: forecast for 2012, biotechnology
Source: BIOtechNOW, 2012-02-14.